Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
NCT07411378 on ClinicalTrials.gov · last registry update 2026-02-13
Registered but not yet open, with 164 participants planned. Due to report June 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from baseline in the knee extension strength at 21 weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Biophytis
- Sponsor type
- Industry
- Enrollment
- 164
- Started
- 2026-07
- Primary completion
- 2027-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from baseline in the knee extension strength at 21 weeks
Conditions studied
Muscle Wasting · Obesity & Overweight · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.